3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
113
Colorectal Neoplasms
73
Stomach Neoplasms
48
Pancreatic Neoplasms
45
Rectal Neoplasms
40
Neoplasms
29
Neoplasm Metastasis
29
Colonic Neoplasms
18
Esophageal Neoplasms
16
Triple Negative Breast Neoplasms
13
Adenocarcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Gallbladder Neoplasms
9
Bile Duct Neoplasms
8
Brain Neoplasms
7
Adenocarcinoma Of Esophagus
7
Liver Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Cholangiocarcinoma
5
Breast Neoplasms, Male
5
Somatostatinoma
4
Head and Neck Neoplasms
4
Carcinoma, Hepatocellular
4
Biliary Tract Neoplasms
4
Gastrointestinal Neoplasms
3
Gastrinoma
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Solid Tumor
2
Interventions
Ramucirumab
1
Fluorouracil
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metastatic Gastric Adenocarcinoma
×
Capecitabine
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts